Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma
Cho H, Costa L, Davies F, Neparidze N, Vij R, Feng Y, Teterina A, Fritsch E, Wenger M, Kaufman J. Atezolizumab in Combination with Daratumumab with or without Lenalidomide or Pomalidomide: A Phase Ib Study in Patients with Multiple Myeloma. Blood 2018, 132: 597. DOI: 10.1182/blood-2018-99-114960.Peer-Reviewed Original ResearchObjective response rateAdverse eventsMultiple myelomaMM ptsGenentech IncGrade 3Response assessmentNon-small cell lung cancerHigh-risk cytogenetic featuresAdvisory CommitteeF. Hoffmann-La Roche LtdR Multiple MyelomaGood partial responseGrade 4 thrombocytopeniaImmune checkpoint inhibitorsPhase Ib studyNew safety signalsProgression-free survivalRefractory multiple myelomaSerious adverse eventsCell lung cancerDuration of responseAnti-myeloma activityBenefit-risk profileData monitoring committee